Study on Onvansertib with Chemotherapy and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adults with KRAS or NRAS Mutation

Inclusion Criteria

• Have metastatic colorectal cancer confirmed by lab tests.
• Have a documented KRAS or NRAS mutation.
• Have not received any previous treatment for metastatic cancer.
• Be willing to provide a tissue sample or undergo a biopsy.
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Women of childbearing potential must use contraception or take measures to avoid pregnancy.
• Have recent imaging scans to document all cancer sites.
• Have acceptable organ function as determined by medical tests.

Exclusion Criteria

• Have both KRAS or NRAS and BRAF-V600 mutations or high microsatellite instability.
• Have previously been treated with a VEGF inhibitor like Bevacizumab.
• Have received oxaliplatin treatment within the last 12 months.
• Have a known deficiency in dihydropyrimidine dehydrogenase (DPD).
• Have received any cancer treatment within 28 days before starting the study drug.
• Have untreated or symptomatic brain cancer spread.
• Have gastrointestinal disorders that affect the absorption of oral medications.
• Be unable or unwilling to swallow the study drug.
• Have uncontrolled illnesses.
• Have known allergies to certain chemotherapy drugs.
• Have abnormal bilirubin processing or known Gilbert's syndrome.
• Be using certain strong medications that affect liver enzymes.
• Have a prolonged QT interval on an ECG (QTc greater than 470 milliseconds).